342 related articles for article (PubMed ID: 26541880)
1. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
2. Use of oligonucleotide aptamer ligands to modulate the function of immune receptors.
Gilboa E; McNamara J; Pastor F
Clin Cancer Res; 2013 Mar; 19(5):1054-62. PubMed ID: 23460536
[TBL] [Abstract][Full Text] [Related]
3. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8
Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E
Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy via nucleic acid aptamers.
Khedri M; Rafatpanah H; Abnous K; Ramezani P; Ramezani M
Int Immunopharmacol; 2015 Dec; 29(2):926-936. PubMed ID: 26603636
[TBL] [Abstract][Full Text] [Related]
6. Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy.
Schrand B; Berezhnoy A; Brenneman R; Williams A; Levay A; Kong LY; Rao G; Zhou S; Heimberger AB; Gilboa E
Cancer Immunol Res; 2014 Sep; 2(9):867-77. PubMed ID: 24938283
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.
Zhu H; Li J; Zhang XB; Ye M; Tan W
ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749
[TBL] [Abstract][Full Text] [Related]
8. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.
Kim M; Kim DM; Kim KS; Jung W; Kim DE
Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327
[TBL] [Abstract][Full Text] [Related]
9. A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice.
Gefen T; Castro I; Muharemagic D; Puplampu-Dove Y; Patel S; Gilboa E
Mol Ther; 2017 Oct; 25(10):2280-2288. PubMed ID: 28800954
[TBL] [Abstract][Full Text] [Related]
10. Aptamer applications for targeted cancer therapy.
Barbas AS; Mi J; Clary BM; White RR
Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
[TBL] [Abstract][Full Text] [Related]
11. Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP; Giangrande PH
Ther Deliv; 2013 Dec; 4(12):1527-46. PubMed ID: 24304250
[TBL] [Abstract][Full Text] [Related]
12. Enhancing anti-PD-1 Immunotherapy by Nanomicelles Self-Assembled from Multivalent Aptamer Drug Conjugates.
Geng Z; Wang L; Liu K; Liu J; Tan W
Angew Chem Int Ed Engl; 2021 Jul; 60(28):15459-15465. PubMed ID: 33904236
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.
Benedetto G; Vestal CG; Richardson C
Target Oncol; 2015 Dec; 10(4):467-85. PubMed ID: 25989948
[TBL] [Abstract][Full Text] [Related]
14. Aptamer-functionalized liposomes for targeted cancer therapy.
Moosavian SA; Sahebkar A
Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
[TBL] [Abstract][Full Text] [Related]
15. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
16. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles.
Sivakumar P; Kim S; Kang HC; Shim MS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426
[TBL] [Abstract][Full Text] [Related]
17. Aptamers as the chaperones (Aptachaperones) of drugs-from siRNAs to DNA nanorobots.
Citartan M; Kaur H; Presela R; Tang TH
Int J Pharm; 2019 Aug; 567():118483. PubMed ID: 31260780
[TBL] [Abstract][Full Text] [Related]
18. Towards targeted cancer therapy: Aptamer or oncolytic virus?
Tan KX; Danquah MK; Sidhu A; Ongkudon CM; Lau SY
Eur J Pharm Sci; 2017 Jan; 96():8-19. PubMed ID: 27593990
[TBL] [Abstract][Full Text] [Related]
19. Manipulating the in vivo immune response by targeted gene knockdown.
Lieberman J
Curr Opin Immunol; 2015 Aug; 35():63-72. PubMed ID: 26149459
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
